Navigation Links
Hormone therapy for prostate cancer does not appear to increase cardiac deaths
Date:12/10/2008

Treating prostate cancer patients with drugs that block hormonal activity does not appear to increase the risk of death from cardiovascular disease, according to a study led by Massachusetts General Hospital (MGH) researchers. While a 2006 report from members of the same study team found that treatment with gonadotropin-releasing hormone (GnRH) agonists increased the risk of diabetes and heart disease, the current study is the first to examine whether treatment actually increased heart-disease-related deaths. In their Journal of Clinical Oncology report, which has been released online, the researchers note that GnRH agonist treatment has a number of adverse side effects, which should be kept in mind when determining treatment strategies.

"Hormonal therapy for prostate cancer has become routine for many patients, so it's even more important to understand the potential adverse effects of treatment," says lead author Jason Efstathiou, MD, PhD, of the MGH Cancer Center. "Given recent concerns about the safety and impact on cardiac health of hormonal therapies particularly GnRN agonists our study is quite timely."

Since the male hormones called androgens can accelerate the development of prostate cancer, reducing their activity is a standard part of treating the disease. Most commonly this is done with GnRH agonists that block the production of all sex hormones. GnRH agonist therapy is routinely administered to men whose cancer has spread beyond the prostate gland, and its use in patients whose tumors appear confined to the prostate is becoming more common. It is estimated that one-third of the two million prostate cancer survivors in the U.S. are currently receiving this therapy, making understanding the potential adverse effects of treatment particularly important.

The earlier report from a Harvard Medical School team including Matthew Smith, MD, PhD, of the MGH Cancer Center, who is corresponding author of the cur
'/>"/>

Contact: Katie Marquedant
kmarquedant@partners.org
617-726-0337
Massachusetts General Hospital
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Drop in breast cancer incidence linked to hormone use, not mammograms
2. Researchers develop long-lasting growth hormone
3. One of the Largest Post-WHI Physician Surveys Shows More Education is Needed: Patient Misinformation About Hormone Therapy Remains High
4. Less than one-third of women aware of landmark hormone therapy study, Stanford researcher finds
5. Most Women Unaware of Hormone Replacement Study
6. Survival data presented from phase II study of hormone-resistant prostate cancer patients
7. Hormone May Play Key Part in Creating Memories
8. Hormone Therapy for Prostate Cancer Linked to Heart Risks
9. Wyeth to Appeal Nevada Hormone Therapy Trial Verdict
10. New data on hormone therapy must lead to re-evaluation of official guidelines
11. From Hot Flashes to Breast Cancer: ZRT Labs Hormone Testing Catches On As Women Consider Safer, More Natural Options.

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/8/2009)... UCW Academy of Health holds open ... Victoria, BC (Vocus) November 8, 2009 -- UCW Aca...areer in British Columbia’s health care indu...nesday, November 25, 2009. , ,UCW Academy of Heal...tration, nursing and social services, designs its ...
(Date:11/8/2009)... New book called "Preventing ...by Dr. Roberto Giraldo shows that AIDS is a result...ariety of so-called immune system stressor agents,...al and most of all, emotional. , ...rom Nov. 6 – 8, 2009, cell biologists, physi...
(Date:11/8/2009)...HINGTON, Nov. 7 Today, ...tts, Kaptur, Dahlkemper, Smith, Ellsworth and Lipi...America Act" (H.R. 3962). The amendment maintains ...or abortion and for benefits packages that include...se who receive affordability credits and those who...
(Date:11/8/2009)...lls for Swift Passage of H.R. 3961 to Secure the S...swire-USNewswire/ -- Statement Attributable to: J....ssociation. ,, (Logo: http://www.newscom.com/...ails the passage of the House health reform bill, ...ents and physicians and calls for swift passage of...
(Date:11/8/2009)...LYWOOD, Calif., Nov. 8 ...n of Babies luncheon to recognize prominent indivi...ren and who are role models for March of Dimes com...of the March of Dimes November Prematurity Awarene...were urged to join the fight for preemies! ,, (...
Breaking Medicine News(10 mins):Health News:College Invites Public to Explore Career Options in Health Care 2Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 2Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 3Health News:Family Research Council Praises Passage of Pro-life Amendment to Health Care Bill 2Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2Health News:Hollywood Stars Joined in a Celebration of Babies 2Health News:Hollywood Stars Joined in a Celebration of Babies 3
... yielded success in controlling certain errors in ...rnative to conventional drugs has won for Prof. He... Hebrew University of Jerusalem, one of this year,... the 71st meeting of the board. , The concept beh...
...o really pan out, expert warns , , THURSDA...ic breast cancer who developed an immune response ...as those who didn,t have an immune response, new r...professor of medicine at the University of Pennsyl...
...ighest standard for contact lens UV protection, S... Lenses for ASTIGMATISM, today became the fourth c... receive the AOA Seal of Acceptance for,Ultraviole...metry,s Meeting(TM), the annual meeting of the Ame...
...ed in One of Canada,s Largest Academic Cancer Cent...ated (Nasdaq: ARAY ), a global leader in the fiel...italier de l,Universite de Montreal (CHUM),has pur...iation oncology centers in Canada, will,utilize th...
...e time is right and the,wording is excellent," sai...Life. "This bill recognizes the God-given Right to...t compromise, it will end the slaughter of,innocen...iary., "Our founding fathers could never have ima...
...e 26 Impliant, Inc., a developer of,novel spine a...announced,that it has resumed European clinical ac... Arthroplasty device designed to treat spinal sten...Sutcliffe, MB ChB, FRCS., (Logo: http://www.news...
Other Medicine News:Health News:RNA engineering to combat series of illnesses wins Kaye Award for Hebrew University dean 2Health News:RNA engineering to combat series of illnesses wins Kaye Award for Hebrew University dean 3Health News:Breast Cancer Vaccines Look Promising 2Health News:Breast Cancer Vaccines Look Promising 3Health News:American Optometric Association Awards Acuvue(R) Oasys(TM) for Astigmatism With Seal of Acceptance for UV Absorbing Contact Lenses 2Health News:American Optometric Association Awards Acuvue(R) Oasys(TM) for Astigmatism With Seal of Acceptance for UV Absorbing Contact Lenses 3Health News:First CyberKnife System to be Installed in Canada 2Health News:First CyberKnife System to be Installed in Canada 3Health News:First CyberKnife System to be Installed in Canada 4Health News:Impliant Restarts European Clinical Activities for Patented TOPS(TM) Spine System 2
(Date:11/6/2009)... , SARASOTA, Fla., Nov. 6 /PRNewswire-FirstCa...y announced that it has signed a definitive agreem...of proprietary medical devices. The Verathon Boar...e closing is subject to customary regulatory appro... approval. The parties expect the closing to be c...
(Date:11/6/2009)... , CHARLESTON, S.C., Nov. 6 /PRNewswire-USN...ll be stopping in South Carolina and Georgia throu...in order to help uninsured and financially-struggl...rovide prescription medicines for free or nearly f...ng 10.2 percent, the Partnership for Prescription ...
(Date:11/6/2009)... , PRINCETON, N.J., Nov. 6 /PRNewswire-FirstC...rd: DSCI), a provider of advanced wound care produ...2009 results before market on Monday, November 16,...t same day to discuss the results at 11:00 am EST....mestic) or (857) 350-1684 (international), with pa...
Breaking Medicine Technology:Roper Industries Announces Two Acquisitions to Enhance Growth in Medical and Toll & Traffic Businesses 2Roper Industries Announces Two Acquisitions to Enhance Growth in Medical and Toll & Traffic Businesses 3Partnership for Prescription Assistance Prepared to Help Southern Workers Hurt by Recession 2Partnership for Prescription Assistance Prepared to Help Southern Workers Hurt by Recession 3Derma Sciences Announces Date of Its Third Quarter 2009 Earnings Release and Conference Call 2Pesticides Linked to Blood Disorder 49387 1Pesticides Linked to Blood Disorder 49387 2Accordia Global Health Foundation Calls for Greater Investment to Build African Healthcare Leadership 49384 1Accordia Global Health Foundation Calls for Greater Investment to Build African Healthcare Leadership 49384 2Accordia Global Health Foundation Calls for Greater Investment to Build African Healthcare Leadership 49384 3Aerobically unfit young adults on road to diabetes in middle age 49381 1Aerobically unfit young adults on road to diabetes in middle age 49381 2
... Discuss Results to Be Held at 9:00 A.M. -, EXTON...: VPHM ) first quarter financial results for 2008...0, 2008 before the open of the,U.S. financial mark... live audio webcast at 9:00,a.m. Eastern Time on t...a,management will discuss the 2008 first quarter f...
... 14 Micromet, Inc.,(Nasdaq: MITI ), a biopharmac...bodies for the treatment of cancer, inflammation a...eting of the American Association for,Cancer Resea...mercial,anti-cancer antibodies trastuzumab (Hercep...ristol-Myers Squibb, Imclone, Merck Serono), and,p...
Other Medicine Technology:ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008 2Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 2Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 3Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 4Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 5
BUN (Urea Nitrogen)
Bilirubin Direct Reagent
...e is the first microplate spectrophotometer design...week. With rugged hardware, proven optical perform...arrier of traditional spectrophotometry to obtain ...rument can easily read up to eight, 1 cm Biocell c...
LS 45 Luminescence Spectrometer, 120V
Medicine Products: